FDA approves Tixel noninvasive skin resurfacing technology to treat periorbital wrinkles
Click Here to Manage Email Alerts
Key takeaways:
- Tixel works by delivering short bursts of thermal energy into the skin’s surface without damaging the deeper tissues.
- Recovery is a fraction of the time compared with laser.
The FDA has approved Tixel, an innovative noninvasive skin resurfacing technology, for periorbital wrinkle treatment, Sentient announced in a press release.
According to Sentient, periorbital wrinkles — the fine lines around and under the eyes that are commonly known as “crow’s feet” — are one of the earliest and most difficult signs of aging to treat due to the skin around the eyes being thinner and more delicate than the surrounding facial skin.
“The FDA’s approval for treating periorbital wrinkles with Tixel by Sentient is a game-changer for patients and for the aesthetics industry,” Chris Cella, CEO of Sentient, said in the release. “It reaffirms Sentient’s dedication to innovation and delivering safe and effective outcomes for our patients.”
Tixel works by delivering short bursts of thermal energy into the skin’s surface without causing damage to deeper tissues, according to the release. By combining heat and the forward motion of a medical-grade titanium tip, the device transfers thermal energy via a brief application directly to the skin’s top layers. This transfer creates controlled micro-damage that stimulates collagen production and corrects wrinkles.
Tixel does not emit radiation and, therefore, does not require ocular shields that are typically used during laser treatments. Pain and social downtime after treatment are minimal compared with treatments using lasers and radio frequency, according to the release. Makeup can also be used the day after treatment.
Since 2011, Tixel has been used in Europe, and the technology first received FDA clearance 2 years ago for skin resurfacing of all skin types.
Perspective
Back to Top
Read more about
Click Here to Manage Email Alerts